Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

The role of kinin B1 receptor and the effect of angiotensin I-converting enzyme inhibition on acute gout attacks in rodents

Official URL:https://doi.org/10.1136/annrheumdis-2014-205739
PubMed:View item in PubMed
Creators Name:Silva, C.R. and Oliveira, S.M. and Hoffmeister, C. and Funck, V. and Guerra, G.P. and Trevisan, G. and Tonello, R. and Rossato, M.F. and Pesquero, J.B. and Bader, M. and Oliveira, M.S. and McDougall, J.J. and Ferreira, J.
Journal Title:Annals of the Rheumatic Diseases
Journal Abbreviation:Ann Rheum Dis
Volume:75
Number:1
Page Range:260-268
Date:January 2016
Keywords:Arthritis, Gout, Inflammation, Animals, Mice, Rats
Abstract:OBJECTIVE: Verify the role of the kinin B1 receptors (B1R) and the effect of ACE inhibitors (ACEi) on acute gout induced by monosodium urate (MSU) crystals in rodents. METHODS: Painful (overt pain and allodynia) and inflammatory parameters (joint oedema, leukocyte trafficking, interleukin-1beta levels) of acute gout attacks were assessed several hours after an intra-articular injection of MSU (1.25 or 0.5 mg/articulation) into the ankle of rats or mice, respectively. The role of B1R was investigated using pharmacological antagonism or gene deletion. Additionally, B1R immunoreactivity in ankle tissue and sensory neurons, kininase I activity and des-Arg9-bradykinin synovial levels were also measured. Similar tools were used to investigate the effects of ACEi on a low dose of MSU (0.0125 mg/articulation)-induced inflammation. RESULTS: Kinin B1R antagonism or gene deletion largely reduced all painful and inflammatory signs of gout. Furthermore, MSU increased B1R expression in articular tissues, the content of the B1 agonist des-Arg9-bradykinin and the activity of the B1 agonist-forming enzyme kininase I. A low dose of MSU crystals, which did not induce inflammation in control animals, caused signs of acute gout attacks in ACEi-treated animals that were B1R-dependent. CONCLUSIONS: Kinin B1R contributes to acute gouty attacks, including the ones facilitated by ACEi. Therefore, B1R is a potential therapeutic target for the treatment and prophylaxis of gout, especially in patients taking ACEi.
ISSN:0003-4967
Publisher:BMJ Publishing Group (U.K.)
Item Type:Article

Repository Staff Only: item control page

Open Access
MDC Library